How To Play An Abiomed Long Trade

My weekly stock pick comes at a time when it’s sure hard to go long in the market, but here goes. This week's stock pick is Abiomed (ABMD).

Abiomed provides medical products and services in the area of circulatory care. The Company’s products can be used in a range of clinical settings, including by heart surgeons for patients in profound shock and by interventional cardiologists for patients who are in pre-shock or in need of prophylactic support in the cardiac catheterization lab (cath lab). The two products of the Company designed for heart recovery following acute events are the BVS 5000 biventricular support system [BVS] and the AB5000 circulatory support system [AB5000]. There are two primary types of devices used in the cath lab and surgery suite for circulatory support for pre-shock and profound shock patients: intra-aortic balloons [IABs], and ventricular assist devices [VADs].

Basic Fundamental Info: Market Capitalization $445M. 40% Institutionally Owned. No Earnings Currently. Debt to Equity 10%. Growth Estimates. Current Qtr.16.0%. Next Qtr. 27.3%. This Year 13.6%. Next Year 39.3%. Next 5 Years (per annum) 22.3%. Price/Sales 8.83. Price/Book 4.13.

Technically, here's the trade setup for Monday Jan 21. Buy Stop $14.41. Stop-Loss $13.43. Take Profit Very Short Term $16.06 to $16.66, Short Term $17.29 to $17.94, Intermediate Term 19.83 to $20.57, Long Term $23.18 to 24.04. Take profit subject to stop-loss not taking out the position.

Latest Abiomed FDA Approval News January 7th, 2008

Abiomed Announces AB5000 Portable Circulatory Support Driver. Reliable, Lightweight, and Quiet Driver Runs Abiomed's AB5000 VAD. Enables Discharge to Enhance Patient Quality of Life. FDA Approval Received for Expanded One Year Reliability Label on AB5000 VAD.

The combination of Abiomed's new Portable Driver and its FDA-approved AB5000 VAD provides support of acute heart failure patients. In many cases, profound shock patients require biventricular support (both sides of the heart). The AB5000 can assume the pumping function of a patient's failing heart, allowing the heart to rest, heal and potentially recover. AB5000 is designed to provide either uni-ventricular or bi-ventricular support. Abiomed also announced today that it has received FDA labeling approval of one year bench reliability for its AB5000 VAD, which is expected to complement the Portable Driver reliability.

"My experience with the AB5000 Circulatory Support System has been excellent in treating over 30 patients with support duration of up to 40 days," said Louis Samuels, M.D., FACS Surgical Director Heart Failure and Transplant, Director Artificial Heart & Ventricular Assist Device Program, Lankenau Hospital. "The new Portable Driver is lightweight and quiet, demonstrates reliable performance, and has the potential to improve patient care while lowering costs to hospitals."

"There is a clinical need to provide patients requiring VAD support a greater degree of mobility during treatment aimed at myocardial recovery," said John V. Conte, M.D., Associate Director of Cardiac Surgery, Associate Professor of Surgery, Director of the Heart and Lung Transplantation, Director of the Ventricular Assist Device Program, Johns Hopkins Hospital. "The expected durability of this portable driver is a nice match with the AB5000 VAD and could provide an integrated and effective solution for patients requiring uni-ventricular or bi-ventricular support."

Abiomed's Portable Driver is a powerful bi-ventricular system which delivers the pressures and vacuums equivalent to Abiomed's AB5000 console and its recently approved iPulse console, at only 18 pounds in weight. Internal testing of the Portable Driver and the AB5000 Ventricle has demonstrated high reliability. This testing showed that the Portable Driver is capable of providing full support for a year's intended use. The unit is expected to require low maintenance, approximately every 5,000 hours of operation, which is estimated to be three times longer than existing portable consoles that weigh twice as much. Abiomed's Portable Driver was designed with the latest smart battery technology for extended power capability and the quiet operation of the Portable Driver provides for minimal disruption of the patient's quality of life at-home or while in care centers.

In addition to providing an advanced clinical option for heart centers, Abiomed's Portable Driver is expected to be cost-effective for hospitals. Procedures are supported with associated in-hospital Medicare reimbursement that range from approximately $80,000 to $171,000 per patient stay, with the additional potential for direct console cost reimbursement per patient discharged.

Abiomed's Portable Driver has not yet been approved by the U.S. Food and Drug Administration [FDA]. The Company plans to pursue an investigational device exemption [IDE] to conduct a discharge study, which is expected to be submitted in early calendar 2008. Daniel Goldstein, M.D., Associate Professor, Department of Cardiothoracic Surgery, Albert Einstein College of Medicine, Director, Cardiac Transplantation and Mechanical Assistance Programs, Co-Director, Center for Advanced Cardiac Therapy, Montefiore Medical Center, is the principal investigator for the study. "I am excited to begin this study as this new device shows the potential to provide an additional alternative for heart failure patients to improve their quality of life while we focus on heart recovery," said Dr. Goldstein.

The AB5000 VAD is also approved in Europe under CE-mark and has supported patients for up to 312 days. Abiomed expects to start supporting patients with the Portable Driver in Europe in its fiscal fourth quarter ended March 31, 2008 with CE-mark approval. Outside of the U.S., the AB5000 is used as a bridge-to-recovery [BTR] and bridge-to-transplant [BTT] device, and the Portable Driver is expected to greatly enhance the Company's BTT market opportunity.

"The physicians still treat many bi-ventricular patients and want the flexibility to discharge," said Michael R. Minogue, Chairman, CEO and President of Abiomed. "From a business perspective, we believe the Portable Driver will increase the utilization of our AB5000 disposables at heart centers globally."

Abiomed's AB5000 has FDA approvals for all acute heart failure indications. The current installed base of Abiomed's AB5000 Circulatory Support System, prior to the announcement of this Portable Driver and Abiomed's iPulse combination console, is comprised of greater than 50% of the 119 U.S. transplant hospitals and greater than 22% of the 866 U.S. open heart hospitals.

Disclosure: Author is long ABMD.

Comments

[Michael Mic...:]

I'm reissuing a buy on ABMD at current price of 17.92 starting today July 8th, 2008. Looking for 21.54 to 22.07 to take profit.

Good day!

2008 Jul 07 03:02 AM